¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mature cell leukemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • helper cell
    µµ¿ò¼¼Æ÷, Á¶·Â¼¼Æ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä, Ç÷±¸Çü¼º¼¼Æ÷À̽Ä
  • hairy cell
    Åиð¾ç¼¼Æ÷
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • hepatosplenic T-cell lymphoma
    °£ºñÀåT¼¼Æ÷¸²ÇÁÁ¾
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • heterotrophic cell
    Á¾¼Ó¿µ¾ç¼¼Æ÷
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • horizontal cell
    ¼öÆò¼¼Æ÷
  • horny cell
    °¢Áú¼¼Æ÷
  • human diploid cell vaccine
    »ç¶÷µÎ¹è¼ö¼¼Æ÷¹é½Å
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T-cell lymphotropic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
  • Hurthle cell adenoma
    ÈÖ¸£Æ²·¹¼¼Æ÷»ùÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • lymphopoietic cell
    ¸²ÇÁ±¸»ý¼º¼¼Æ÷
  • marrow cell
    °ñ¼ö¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    ²ÀÁö¹úÁý
  • matrix cell
    ±âÁú¼¼Æ÷, ÅйÙÅÁÁú¼¼Æ÷
  • memory cell
    ¸é¿ª±â¾ï¼¼Æ÷
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • microglial cell
    ¹Ì¼¼¾Æ±³¼¼Æ÷
  • mitotic cell
    ºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷
  • mossy cell
    À̳¢¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • granular cell tumo(u)r
    °ú¸³¼¼Æ÷ Á¾¾ç
  • granule cell
    °ú¸³¼¼Æ÷(¡­á¬øà).
  • granule cell
    °ú¸³¼¼Æ÷
  • granuloma,giant cell
    °Å´ë¼¼Æ÷¼º À°¾ÆÁ¾
  • granulopoietic cell
    °ú¸³__¶Ç÷¼¼Æ__
  • granulosa cell
    °ú¸³¸·¼¼Æ÷(¡­á¬øà).
  • granulosa cell carcinoma
    (³­¼Ò)°ú¸³¸·¼¼Æ÷ ¾ÏÁ¾(Õ°áµÎ¨í£Ø¯á¬øà ðþ).
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç.
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa lutein cell
    °ú¸³ÃþȲü¼¼Æ÷, °ú¸³¸·È²Ã¼¼¼Æ÷(¡­Ø¯üÜô÷á¬øà).
  • granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
  • granulosa lutein cell
    °ú¸³ÃþȲü¼¼Æ÷, °ú¸³ ¸·È²Ã¼¼¼Æ÷(¡­Ø¯üÜô÷á¬øà).
  • granulosa theca cell tumor
    °ú¸³Çù¸·¼¼Æ÷Á¾ ¾ç(¡­úõØ¯á¬øàðþåË).
  • granulosa theca cell tumor
    °ú¸³Çù¸·¼¼Æ÷Á¾ ¾ç(¡­úõØ¯á¬øàðþåË)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • basal cell nevus syndrome
    ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº(¡­Ù½Úèñøý¦ÏØ).
  • basal cell nevus syndrome
    ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº(¡­Ù½Úèñøý¦ÏØ)
  • basal cell papilloma
    ±âÀú¼¼Æ÷À¯µÎÁ¾
  • basal epithelial cell
    ±âÀú»óÇǼ¼Æ÷
  • basal epithelial cell
    ¹Ù´Ú»óÇǼ¼Æ÷
  • basal squmous cell epithelioma
    ±âÀú»óÇǼ¼Æ÷Á¾
  • basaloid cell
    ±âÀú¾ç¼¼Æ÷
  • base of cell
    ¼¼Æ÷¹Ù´Ú
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â(¼º) ¼¼Æ÷(?ËṴ̂).
  • basophilic cell
    È£¿°±â(¼º) ¼¼Æ÷(¡­á¬øà).
  • basophilic cell
    È£¿°±â¼º¼¼Æ÷
  • basosquamous cell carcinoma
    ±âÀú ÆíÆò¼¼Æ÷ ¾Ï(Á¾)
  • basosqumaous cell acanthoma
    ±âÀú ÆíÆò¼¼Æ÷±Ø¼¼Æ÷Á¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
FDC factor-dependent cell [line]; follicular dendritic cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
TCRBCL T cell rich B cell lymphoma
APC T-cell-antigen-presenting cell
B cell cell
G cell gastrin cell
TCR 1(+)-T-cell receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • motility of cell
    ¿îµ¿¼º ¼¼Æ÷
  • motor cell
    ¿îµ¿ ½Å°æ ¼¼Æ÷
  • mucous cell
    Á¡¾× ¼¼Æ÷
  • mucous neck cell
    Á¡¾×°æ ¼¼Æ÷
  • mucus-secreting cell
    Á¡¾× ºÐºñ ¼¼Æ÷
  • multilocular fat cell
    ¹µÄ­ Áö¹æ ¼¼Æ÷
  • multinucleated cell
    ´ÙÇÙ ¼¼Æ÷
  • multinucleated giant cell
    ´ÙÇÙ °Å´ë ¼¼Æ÷, °Å´ë ´ÙÇÙ ¼¼Æ÷, ´ÙÇÙ °Å¼¼Æ÷
  • multipolar nerve cell
    ¹µ ±Ø ½Å°æ ¼¼Æ÷, ´Ù±Ø ½Å°æ ¼¼Æ÷
  • muscle cell
    ±Ù ¼¼Æ÷
    ´Éµ¿ÀûÀ¸·Î ¼öÃ༺À» º¸ÀÌ´Â µ¿¹°Ã¼³»ÀÇ ¼¼Æ÷. ±ÙÀ° ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ±Ù Á¶Á÷À» ±¸¼ºÇÏ´Â °æ¿ì °¢°¢ÀÇ ±Ù ¼¼Æ÷´Â ÀϹÝÀûÀ¸·Î ¹æÃß»ó ¶Ç´Â ¼¶À¯»óÀ» ¶í´Ù. ÇØ¸éµ¿¹°Àº ±ÙÁ¶Á÷ÀÌ ¾øÀ¸³ª, ±Ô°¢ ÇØ¸é·ù¿¡¼­´Â üǥÀÇ ÆíÆò»óÇÇ ¼¼Æ÷°¡ ¾ó¸¶°£ ¼öÃ༺À» °¡Áö¸ç, üǥ ƯÈ÷ À¯Ãâ°ø ÁÖº¯¿¡ ¹Ì¿À»çÀÌÆ®¶ó°í ÇÏ´Â ±ä ¹æÃßÇüÀÇ ¼öÃ༺ ¼¼Æ÷°¡ Á¸ÀçÇÑ´Ù. ¶Ç ¼®È¸ ÇØ¸é·ùÀÇ ¼Ò°ø ¼¼Æ÷¿¡µµ ¼öÃ༺ÀÌ ÀÎÁ¤µÈ´Ù. À̵éÀº ¾î¶² Á¾·ùÀÇ ¿ø»ýµ¿¹° ¸ö Àüü¿¡ ³ªÅ¸³ª´Â ¼öÃ༺°ú ´õºÒ¾î ±Ù ¼¼Æ÷°¡ ³ªÅ¸³ª´Â ½ÃÀÛ ÇüÅ·Π°£ÁֵȴÙ. °­À嵿¹°ÀÇ Æú¸³Çü¿¡¼­´Â ¿Ü¹è¿± ¼¼Æ÷ Ãþ ¼Ó¿¡ ÀÖ´Â »óÇÇ ±Ù ¼¼Æ÷¿¡ ÁøÁ¤ÇÑ ±Ù¿ø¼¶À¯°¡ ÀÖ´Ù. À̰ÍÀº °¡Àå ÈçÈ÷ ÀÖ´Â ¿øÁÖ»óÇÇ ¼¼Æ÷, ÁïÁöÁö ¼¼Æ÷ÀÇ ±âÀúºÎ°¡ ¹æÃßÇüÀ¸·Î ´Ã¾î³ª¼­ ±× ºÎºÐ¿¡ ÇÑÇØ¼­ ±Ù¿ø¼¶À¯°¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î, üǥÀÇ »óÇÇ ¼¼Æ÷¿¡¼­ ±Ù¼¼Æ÷·Î ºÐÈ­ÇÏ´Â µµÁßÀÇ °ÍÀÌ´Ù. ÇØÆÄ¸® Çü¿¡¼­´Â ¹æÃßÇü ±Ù ¼¼Æ÷°¡ ¿Ï¼ºµÈ´Ù. ÆíÇüµ¿¹° À̻󿡼­´Â ÇDZÙÃþ, ±â°ü±Ù µî ºÐÈ­°¡ ÇöÀúÇÏ´Ù.
  • muscle-cell
    ±Ù ¼¼Æ÷
  • mycosis cell
    ¸¶ÀÌÄڽýº ¼¼Æ÷, Áø±Õ ¼¼Æ÷
    ¸¹Àº ºñÁ¤Çü ¸²ÇÁ°è ¼¼Æ÷ÀÇ Çϳª·Î¼­ °ú¿°»ö¼ºÀÇ ½ÉÇÑ È¸¼±»ó ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ¿øÁ¶/À¯µµ ¼¼Æ÷ Ç¥ÇöÇüÀÇ T ¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ¸·Î º¸ÀδÙ. ¿ë»ó Áø±ÕÁõ¿¡¼­ »óÇdzª ÆÄ¿ìÆ®¸®¾î
  • myoid cell
    ±ÙÀ°¾ç ¼¼Æ÷
  • natural kil1er cell
    ÀÚ¿¬ »ì¼¼Æ÷
    ¼±Ãµ¼º ¸é¿ªÀÇ Áß¿ä ÀÎÀÚ. ¼¼Æ÷ ³»¿¡ azuro
  • nerre cell body
    ½Å°æ¿øÃ¼, ½Å°æ ¼¼Æ÷ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
cell adhesion See: adhesins, cadherins, cell adhesion molecules (CAMs), contact sites A, DLVO theory, integrins, sorting out, uvomorulin and various specialised junctions (adherens junctions, desmosomes, focal adhesions, gap junction and zonula occludens).
(18 Nov 1997)
cell adhesion kinase <enzyme> From hela cells; involved in cell-cell interactions; genbank l20817
Registry number: EC 2.7.1.-
Synonym: cak protein
(26 Jun 1999)
cell adhesion molecule <molecular biology> Although this could mean any molecule involved in cellular adhesive phenomena, it has acquired a more restricted sense, namely a molecule on the surface of animal tissue cells, antibodies (or Fab fragments) against that specifically inhibit some form of intercellular adhesion.
Examples are Liver Cell Adhesion Molecule and Neural Cell Adhesion Molecule, both named from tissues in which first detected, although their occurrence is not in fact restricted to these.
Acronym: CAM
(26 Nov 1998)
cell adhesion molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
(12 Dec 1998)
cell adhesion molecules, neuronal Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue.
(12 Dec 1998)
cell adhesion molecules, neuron-glia Cell adhesion molecules that mediate neuron-neuron adhesion and neuron-astrocyte adhesion. They are expressed on neurons and schwann cells, but not astrocytes and are involved in neuronal migration, neurite fasciculation, and outgrowth. Ng-cam is immunologically and structurally distinct from ncam (neural cell adhesion molecules).
(12 Dec 1998)
cell aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type.
(12 Dec 1998)
cell aging The decrease in the cell's ability to proliferate with the passing of time. Each cell is programmed for a certain number of cell divisions and at the end of that time proliferation halts. The cell enters a quiescent state after which it experiences cell death via the process of apoptosis.
(12 Dec 1998)
cell behaviour <cell biology> General term for activities of whole cells such as movement, adhesion and proliferation, by analogy with animal behaviour.
(18 Nov 1997)
cell biology <study> The study of the internal workings of cells at the microscopic and molecular level - it is closely linked to molecular biology.
(16 Dec 1997)
cell body Used in reference to neurons, the main part of the cell around the nucleus excluding long processes such as axons and dendrites.
(18 Nov 1997)
cell-bound antibody A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region.
(05 Mar 2000)
renal cell cancer Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine. Also called renal cell carcinoma.
(12 Dec 1998)
renal cell carcinoma <oncology, tumour> The most common form of kidney cancer which occurs when the cells lining the renal tubule undergo cancerous changes. There are approximately 18,000 new cases of renal cell carcinoma (hypernephroma) per year in the U.S. With about 8,000 deaths annually.
Smoking is considered a major risk factor. Kidney dialysis patients are at increased risk for the development of hypernephroma. Family history for renal cell carcinoma is also considered a risk factor.
Symptoms include haematuria, flank pain, abdominal pain, back pain, weight loss and abdominal swelling.
(27 Sep 1997)
cell bridges Slender cytoplasmic strands connecting adjacent cells; in histological sections of the epidermis and other stratified squamous epithelia, the bridge's are processes attached by a desmosome and are shrinkage artifacts of fixation; true bridge's with cytoplasmic confluence exist between incompletely divided germ cells.
Synonym: cell bridges, cytoplasmic bridges.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á